Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-03 (Celestial Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Celestial Therapeutics
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CT-03 is a preclinical mRNA vaccine candidate developed by Celestial Therapeutics for the prevention of Chikungunya virus infection. It is built upon the company's proprietary Stellar-mRNA platform, which is characterized as a self-adjuvanting technology. This platform is designed to enhance vaccine efficacy while significantly reducing reactogenicity, potentially allowing for effective immunization at very low doses compared to traditional mRNA technologies. Celestial Therapeutics, a California-based biotechnology company and resident of Johnson & Johnson Innovations-JLABS, is currently advancing CT-03 through preclinical development.
Beyond the preview
Go deeper on CT-03 (Celestial Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-03 (Celestial Therapeutics).